cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Morphic Holding Inc
4 own
4 watching
Current Price
$34.55
$0.21
(0.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,331.29M
52-Week High
52-Week High
47.66
52-Week Low
52-Week Low
19.23
Average Volume
Average Volume
0.21M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,331.29M
icon52-Week High47.66
icon52-Week Low19.23
iconAverage Volume0.21M
iconDividend Yield--
iconP/E Ratio--
What does the Morphic Holding Inc do?
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children s Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Read More
How much money does Morphic Holding Inc make?
News & Events about Morphic Holding Inc.
Globe Newswire
30days ago
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic(Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will...
Globe Newswire
2 months ago
First patient dosed in global study of oral 47 integrin inhibitorWALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced ...
Globe Newswire
2 months ago
WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Bruce Rogers, President of Morphic, will participate in a ...
Zolmax
3 months ago
Morphic Holding, Inc. (NASDAQ:MORF Get Rating) has received a consensus rating of Buy from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among ...
Globe Newswire
3 months ago
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved 47 inhibitor WALTHAM, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical ...
Frequently Asked Questions
Frequently Asked Questions
What is Morphic Holding Inc share price today?
plus_minus_icon
Can Indians buy Morphic Holding Inc shares?
plus_minus_icon
How can I buy Morphic Holding Inc shares from India?
plus_minus_icon
Can Fractional shares of Morphic Holding Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Morphic Holding Inc stocks?
plus_minus_icon
What is today’s traded volume of Morphic Holding Inc?
plus_minus_icon
What is today’s market capitalisation of Morphic Holding Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Morphic Holding Inc?
plus_minus_icon
What percentage is Morphic Holding Inc down from its 52-Week High?
plus_minus_icon
What percentage is Morphic Holding Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$34.55
$0.21
(0.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
CHINOOK THERAPEUTICS INC
CHINOOK THERAPEUTICS INC
$24.08
$-1.27 (-5.01 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$20.51
$-0.65 (-3.07 %)
Cassava Sciences Inc
Cassava Sciences Inc
$30.92
$-0.60 (-1.90 %)
Replimune Group Inc
Replimune Group Inc
$28.29
$-0.80 (-2.75 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
CHINOOK THERAPEUTICS INC
CHINOOK THERAPEUTICS INC
$24.08
$-1.27 (-5.01 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$20.51
$-0.65 (-3.07 %)
Cassava Sciences Inc
Cassava Sciences Inc
$30.92
$-0.60 (-1.90 %)
Replimune Group Inc
Replimune Group Inc
$28.29
$-0.80 (-2.75 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00